Regulatable Fusogenic Oncolytic HSV-1 Virus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic viruses lack the ability to selectively target and kill cancer cells while sparing normal cells, leading to restricted therapeutic doses and potential adverse effects due to uncontrolled replication.
Innovation Solution
Development of a regulatable fusogenic oncolytic herpes simplex virus 1 (HSV-1) variant, KTR27-F, which can be tightly controlled by tetracycline, featuring deletions in ICP0 and ICP34.5 genes, a tetracycline operator sequence, and a ribozyme, enhancing syncytium formation and specificity towards cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing oncolytic viruses are used to kill cancer cells, then cancer cell lysis is achieved, but normal cells are also affected and therapeutic dose is restricted
Solution Approach 1:
The patent applies parameter changes by modifying the viral genome to include conditional replication genes (tetR, ribozyme) that change the replication parameters based on tetracycline presence. This allows the virus to switch between high replication in cancer cells and suppressed replication in normal cells, achieving selective cytotoxicity while sparing normal tissues.
Solution Approach 2:
The invention implements dynamics by creating a regulatable virus system where replication is dynamically controlled by tetracycline administration. The virus transitions from a static replication pattern to a dynamic, pharmacologically-controlled replication pattern, enabling real-time adjustment of oncolytic activity to match tumor needs while avoiding harm to normal cells.
2Productivity
If therapeutic dose of oncolytic virus is increased to improve efficacy, then cancer cell killing increases, but adverse effects in normal tissues increase
Solution Approach 1:
The patent uses parameter changes by introducing tetracycline-dependent replication control, allowing the viral replication parameter to be adjusted independently of dose. High cancer cell lysis can be achieved through optimized viral formulation and timing, while tetracycline administration suppresses replication to prevent adverse effects in normal tissues, decoupling efficacy from toxicity.
Solution Approach 2:
The invention implements feedback control where tetracycline administration provides negative feedback to viral replication. The system monitors tumor response and allows pharmacological modulation to prevent over-replication and associated toxicity, creating a self-regulating therapeutic system that adapts to prevent harmful effects.
3Speed
If oncolytic virus replication is allowed to proceed freely, then rapid tumor cell killing occurs, but progeny virus overload occurs after tumor elimination
Solution Approach 1:
The patent applies dynamics by implementing time-dependent replication control where tetracycline is administered during the early phase to enable rapid replication and tumor cell killing, then discontinued or adjusted to prevent progeny virus overload after tumor elimination. This dynamic timing strategy optimizes both speed of action and prevents excessive virus accumulation.
Solution Approach 2:
The invention uses periodic action through scheduled tetracycline administration that enables viral replication during specific windows when tumor cells are most vulnerable, then creates a pause or reduction phase to prevent progeny virus overload. This periodic control allows rapid initial lysis while preventing excessive subsequent replication.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
KTR27-F demonstrates significantly higher replication and cytotoxicity in cancer cells compared to normal cells, with a 21,800-fold higher yield in breast cancer cells and minimal cytotoxicity in normal fibroblasts, offering enhanced safety and therapeutic efficacy.
Implementation Method 1
a ribozyme sequence located in the 5' untranslated region of the ICP27 gene
Implementation Method 2
a tetracycline operator sequence positioned between 6 and 24 nucleotides 3' to the TATA element
Implementation Method 3
a variant gene that increases syncytium formation as compared to wild type
Data Source
AI summary
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides a regulatable fusogenic oncolytic herpes simplex virus-1 that is more effective at selective killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic virus described herein is suitable for treatment of solid tumors, as well as other cancers.